DCTH — Delcath Systems, Inc.

Summary of Delcath Systems, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $19 million from Hepzato and $1.7 million from ChemoSAT, up from $13.7 million and $1.4 million, respectively, in Q4 2024.
• Full Year 2025 Revenue: $85.2 million total, with $78.8 million from Hepzato and $6.4 million from ChemoSAT, compared to $37.2 million in 2024.
• Gross Margins: 85% in Q4 and 86% for the full year.
• Net Loss: $1.9 million in Q4, improved from a $3.4 million loss in Q4 2024; full year net income of $2.7 million compared to a loss of $26.4 million in 2024.
• Adjusted EBITDA: Positive $2.4 million in Q4 and $25.1 million for the full year, up from a loss of $2.5 million in 2024.
• Cash Position: Approximately $91 million in cash and investments, with positive operating cash flow of $8.3 million in Q4 and $22.5 million for the year.

2. Strategic Updates and Business Highlights

• Volume Growth: Achieved over 40% volume growth in 2025, with 28 active treatment centers and plans to expand to 40 by 2026.
• CHOPIN Trial: Anticipated publication of results showing clinical benefits of Hepzato PHP combined with checkpoint inhibitors, expected to drive referrals and prescribing patterns.
• Commercial Strategy: Focused on expanding site capacity, changing prescribing patterns, and developing referral networks, with active engagement from leading cancer centers.
• Clinical Trials: Ongoing trials in metastatic colorectal and breast cancer, with plans to activate additional sites by mid-2026.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projecting at least $100 million, reflecting over 20% growth in Hepzato procedure volume and over 10% growth in ChemoSAT.
• Gross Margin Expectations: Anticipated between 84% and 87% for 2026, with variability due to customer mix and pricing impacts.
• Increased Expenses: Expecting R&D expenses to rise nearly 90% and SG&A expenses to increase by about 50% in 2026 due to commercial expansion and clinical initiatives.

4. Bad News, Challenges, or Points of Concern

• Seasonality: Anticipated seasonal decline in patient volume during Q3, potentially leading to flat or modest growth compared to Q2.
• Market Competition: Ongoing competitive pressures from clinical trials and other therapies may impact patient recruitment and market share.
• Operational Risks: Variability in site activations and patient treatment rates due to staffing challenges and the complexity of clinical trial enrollments.

5. Notable Q&A Insights

• Seasonality Clarification: Management confirmed that they expect a seasonal dip in Q3, influenced by physician schedules and staffing at treatment centers.
• CHOPIN Study Utilization: Plans to leverage CHOPIN results to enhance sales efforts and potentially influence treatment guidelines.
• Referral Development: Emphasis on educating community oncologists to improve patient referrals, particularly for those not currently considering liver-directed therapies.
• Clinical Trial Focus: Management is balancing the need for clinical trial enrollment with maintaining positive cash flow, indicating a healthy financial position allows for strategic investments in growth.

Overall, Delcath Systems demonstrated strong financial performance in 2025, with significant growth in revenue and improved profitability metrics, while outlining strategic initiatives aimed at expanding market presence and enhancing treatment adoption. However, they face challenges related to seasonality, competitive pressures, and the complexities of clinical trial operations.